What is William Blair’s Estimate for Insulet Q4 Earnings?

Insulet Co. (NASDAQ:PODD) – Stock analysts at William Blair upped their Q4 2024 earnings per share estimates for Insulet in a research note issued to investors on Monday, November 11th. William Blair analyst M. Andrew now forecasts that the medical instruments supplier will post earnings of $1.18 per share for the quarter, up from their previous forecast of $0.99. The consensus estimate for Insulet’s current full-year earnings is $3.11 per share. William Blair also issued estimates for Insulet’s Q1 2025 earnings at $0.83 EPS, Q2 2025 earnings at $0.84 EPS and FY2025 earnings at $3.91 EPS.

A number of other brokerages have also recently issued reports on PODD. Raymond James lifted their price objective on Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research note on Monday, October 14th. Sanford C. Bernstein began coverage on Insulet in a research note on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price objective for the company. Barclays lifted their price objective on Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research note on Monday. BTIG Research lifted their price objective on Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Finally, Piper Sandler lifted their price objective on Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a research note on Tuesday, September 17th. Three research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat, Insulet has an average rating of “Moderate Buy” and an average target price of $253.27.

Insulet Trading Down 0.2 %

NASDAQ PODD opened at $275.10 on Wednesday. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet has a twelve month low of $156.00 and a twelve month high of $279.40. The firm has a market capitalization of $19.30 billion, a PE ratio of 47.11, a P/E/G ratio of 4.36 and a beta of 1.22. The stock’s 50 day moving average is $234.83 and its 200 day moving average is $206.03.

Institutional Trading of Insulet

Several hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in Insulet by 2.1% during the first quarter. Vanguard Group Inc. now owns 8,199,114 shares of the medical instruments supplier’s stock valued at $1,405,328,000 after purchasing an additional 169,506 shares during the period. Baillie Gifford & Co. boosted its stake in shares of Insulet by 20.7% in the third quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier’s stock worth $529,669,000 after acquiring an additional 389,639 shares during the period. Clearbridge Investments LLC grew its position in shares of Insulet by 6.0% during the second quarter. Clearbridge Investments LLC now owns 1,339,763 shares of the medical instruments supplier’s stock worth $270,364,000 after purchasing an additional 75,526 shares in the last quarter. American Century Companies Inc. grew its position in shares of Insulet by 18.7% during the second quarter. American Century Companies Inc. now owns 885,669 shares of the medical instruments supplier’s stock worth $178,728,000 after purchasing an additional 139,246 shares in the last quarter. Finally, Westfield Capital Management Co. LP grew its position in shares of Insulet by 27.6% during the third quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock worth $175,697,000 after purchasing an additional 163,388 shares in the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.